/
Other
Tics
112
Pipeline Programs↗
124
Active Trials↗
392
Companies Involved↗
Tics is a highly competitive landscape with 112 programs across 392 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., AstraZeneca, Qilu Pharmaceutical Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 180
Phase 211
Phase 34
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
105 of 107 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 100% of 112 pipeline programs.
Analysis
Trial Status
2,316
clinical trials
Completed1,943 · 84%
Unknown status121 · 5%
Terminated90 · 4%
Recruiting66 · 3%
Withdrawn36 · 2%
Not yet recruiting32 · 1%
Other28 · 1%
Clinical Trials
Trial Activity
2316 trials
Page 1 of 155
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)